The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2025 | Novel agents for the treatment of CLL in Italy
Antonio Cuneo, MD, University of Ferrara, Ferrara, Italy, comments on the availability of novel agents, specifically pirtobrutinib, for treating chronic lymphocytic leukemia (CLL) in Italy. Pirtobrutinib is currently used in patients with double refractory disease, but Dr Cuneo highlights that it is likely to also become available for patients who have failed on ibrutinib. Additionally, Dr Cuneo mentions the collaboration with the GIMEMA group, which allows for the referral of patients with double or triple refractory CLL to specialized centers for salvage therapy with agents such as BTK degraders and bispecific antibodies. This interview took place at the SOHO Italy Annual Conference 2025 in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I will basically refer to the Italian situation, which I know quite well. We have the opportunity to use pirtobrutinib on a main patient program, which has been made available over the last two years and this is mainly used in double refractory patients. These patient will be out of options and pirtobrutinib was an effective drug which was studied in the BRUIN studies in the double refractory patient...
I will basically refer to the Italian situation, which I know quite well. We have the opportunity to use pirtobrutinib on a main patient program, which has been made available over the last two years and this is mainly used in double refractory patients. These patient will be out of options and pirtobrutinib was an effective drug which was studied in the BRUIN studies in the double refractory patient.
We will be able soon after EMA approval to use pirtobrutinib in the relapsed refractory setting after failure of ibrutinib. This follows the Phase III trial that compared pirtobrutinib in this setting of patients against a comparator that included bendamustine-rituximab or idelalisib-rituximab. The excellent median 29 months time to next treatment make pirtobrutinib a viable option for patients who lost their response to ibrutinib. And I think that some patients with relapsed/refractory CLL after ibrutinib will be offered this opportunity in the near future in our country.
We also have an established collaboration within the GIMEMA group, the centers participating to the meetings, exchange information on experimental trials, so that every patient seen in Italy with double refractory or triple refractory CLL can be referred to centers that are able to offer these patients BTK degraders or bispecific monoclonal antibodies so that every Italian patient which would be out of options based on what the national health system is offering can be referred to specialized centers for salvage therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
